CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
Jang Won Son
Endocrinol Metab. 2021;36(1):57-59.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.109

Excel Download

Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
Endocrinology and Metabolism. 2021;36(1):57-59   Crossref logo
Link1 Link2 Link3

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
Endocrinology and Metabolism. 2021;36(1):157-170   Crossref logo
Link1 Link2 Link3

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
Diabetes, Obesity and Metabolism. 2013;16(1):9-21   Crossref logo
Link1 Link2

Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes
The British Journal of Diabetes & Vascular Disease. 2009;9(2):44-52   Crossref logo
Link1 Link2

Therapeutic potential of glucagon-like peptide-1 agonists in insulin-treated diabetes mellitus
Canadian Journal of Diabetes. 2009;33(3):319   Crossref logo
Link1 Link2

Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
Diabetes, Obesity and Metabolism. 2010;13(1):19-25   Crossref logo
Link1 Link2

Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetes
Diabetic Medicine. 2004;21(s1):18-20   Crossref logo
Link1 Link2

Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).
Atherosclerosis. 2018;275:e151   Crossref logo
Link1 Link2

Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge
Diabetes, Obesity and Metabolism. 2020;22(S4):24-34   Crossref logo
Link1 Link2 Link3 Link4

Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):882-888   Crossref logo
Link1 Link2